Key facts
- Notable investors include Lightermed.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Chipwave Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Chipwave Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Chipwave Biotechnology
Operator of organoid-based biomedical testing systems intended for oncology research and drug development. The company offers tumor and normal tissue organoids, in vitro drug efficacy testing systems, and xenotransplantation models that simulate human microenvironments, enabling pharmaceutical companies and precision medicine researchers to conduct accurate preclinical evaluations, accelerate therapeutic discovery, and improve translational outcomes through high-fidelity biological modeling and scenario-specific validation technologies.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Chipwave Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Chipwave Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Chipwave Biotechnology in its N-PORT filings yet. We sweep new filings monthly.